

Table S1: Study Characteristics and JBI Quality Assessment Score

Author	Year	Country	Study Design	Diagnosis method	Total	Number of Case (IgM or IgG positive)	JBI Score Result
Kassem & Morsy [1]	1991	Libya	Cross-sectional	IHA	369	175	8
El-nawawy [2]	1996	Egypt	Cross-sectional	IHA	150	64	7
Dar et al [3]	1997	United Arab Emirates	Cross-sectional	ELISA	1503	344	8
Al-mulhim & Al-qurashi [4]	2001	Saudi Arabia	Cross-sectional	MEIA	175	70	6
Ghazi et al [5]	2002	Saudi Arabia	Cross-sectional	ELISA	926	330	8
Noorbakhsh et al. [6]	2002	Iran	Cross-sectional	ELISA	140	58	8
Elnahas et al [7]	2003	Sudan	Cross-sectional	ELISA	487	171	8
Jumaian [8]	2005	Jordan	Cross-sectional	IFAT	280	133	6
Al-harathi et al [9]	2006	Saudi Arabia	Cross-sectional	ELISA	197	73	8
Sharifi-mood et al. [10]	2006	Iran	Cross-sectional	IFA	200	54	6
Mansouri et al.[11]	2007	Morocco	Cross-sectional	ELISA	2456	1242	7
Iqbal & Khalid [12]	2007	Kuwaiti	Cross-sectional	ELFA	224	150	7
Saeedi & Marjani [13]	2007	Iran	Cross-sectional	ELISA	300	145	8
Abdi et al. [14]	2008	Iran	Cross-sectional	IFA	553	248	8
Fallah et al. [15]	2008	Iran	Cross-sectional	IFA	576	193	8
Ibrahim et al. [16]	2009	Egypt	Cross-sectional	ELISA	101	52	8
Nijem & Al-Amleh [17]	2009	Palestine	Cross-sectional	ELISA	204	57	7
Al-Nahari et al. [18]	2010	Yemen	Cross-sectional	ELISA	463	249	7
(Mohammad et al. [19]	2010	Saudi Arabia	Cross-sectional	ELISA	554	334	8
Sellami et al. [20]	2010	Tunisia	Cross-sectional	ELISA	40566	15879	8

Almogren [21]	2011	Saudi Arabia	Cross-sectional	IHA	2176	825	8
Mohammed [22]	2011	Iraq	Cross-sectional	ELISA	212	80	8
Amany & and Merwad [23]	2012	Egypt	Cross-sectional	IHA	100	40	8
Saad M. Bin Dajem & Almushait [24]	2012	Saudi Arabia	Cross-sectional	ELISA	137	62	7
El Deeb et al. [25]	2012	Egypt	Cross-sectional	ELFA	323	218	8
Maha H. Elamin [26]	2012	Sudan	Cross-sectional	ELISA	188	81	6
Hajsoleimani et al. [27]	2012	Iran	Cross-sectional	ELISA	500	189	8
Babaie et al. [28]	2013	Iran	Cross-sectional	ELISA	419	144	8
(Ben Abdallah et al. [29]	2013	Tunisia	Cross-sectional	ELISA	2070	1123	7
Fakhfakh et al. [30]	2013	Tunisia	Cross-sectional	ELISA	2351	1121	8
Panah Abolghasem Siyadat et al. [31]	2013	Iran	Cross-sectional	ELISA	1057	796	8
Abdel-Raouff & Elbasheir [32]	2014	Sudan	Cross-sectional	ELISA	163	33	7
Ahmed et al. [33]	2014	Egypt	Cross-sectional	ELISA	100	63	7
Almushait et al. [34]	2014	Saudi Arabia	Cross-sectional	ELISA	487	235	8
Aqeely et al. [35]	2014	Saudi Arabia	Cross-sectional	ELISA	195	51	8
Ashankyty [36]	2014	Saudi Arabia	Cross-sectional	ELISA	6076	630	7
Hadi et al. [37]	2014	Iran	Cross-sectional	ELISA	785	135	8
M Laboudi et al [38]	2014	Morocco	Cross-sectional	ELISA	1169	551	8
(Sharbatkhori et al. [39]	2014	Iran	Cross-sectional	ELISA	555	248	7
Yad Yad et al [40]	2014	Iran	Cross-sectional	ELISA	501	144	8
Elsafi et al. [41]	2015	Saudi Arabia	Cross-sectional	CMIA	400	126	7

Kamal et al. [42]	2015	Egypt	Cross-sectional	ELISA	240	78	7
Ahmadpour et al. [43]	2015	Iran	Cross-sectional	ELISA	200	63	8
Akhlaghi et al. [44]	2016	Iran	Cross-sectional	ELISA	468	95	7
Al-Eryani et al. [45]	2016	Yemen	Cross-sectional	ELISA	593	311	8
Alghamdi et al. [46]	2016	Saudi Arabia	Cross-sectional	ELISA	203	79	7
Bassiony et al. [47]	2016	Egypt	Cross-sectional	ELISA	382	223	8
Imam et al. [48]	2016	Saudi Arabia	Cross-sectional	ELISA	150	32	7
Majid et al. [49]	2016	Pakistan	Cross-sectional	IFA	733	135	8
(Mohaghegh et al. [50])	2016	Iran	Cross-sectional	ELISA	350	122	7
Mohamed et al. [51]	2016	Saudi Arabia	Cross-sectional	ELISA	326	74	8
Rostamzadeh Khameneh et al. [52]	2016	Iran	Cross-sectional	ELISA	156	44	7
(Ahmadpour et al. [53])	2017	Iran	Cross-sectional	ELISA	264	81	8
Alanazi et al. [54]	2017	Saudi Arabia	Cross-sectional	ELISA	340	55	7
Garedaghi & Firozivand [55]	2017	Iran	Cross-sectional	ELISA	200	82	8
Ibrahim et al. [56]	2017	Egypt	Cross-sectional	ELISA	364	123	8
(Majda Laboudi & Sadak [57])	2017	Morocco	Cross-sectional	ELISA	128	59	6
Mahdy et al. [58]	2017	Yemen	Cross-sectional	ELISA	359	178	7
Naghili et al. [59]	2017	Iran	Cross-sectional	ELISA	391	267	7
Nahouli et al. [60]	2017	Lebanon	Cross-sectional	ELISA	11000	2471	7
Nazir [61]	2017	Pakistan	Cross-sectional	ELISA	232	132	8
Norouzi et al. [62]	2017	Iran	Cross-sectional	ELISA	2000	173	8

Shieh et al. [63]	2017	Iran	Cross-sectional	ELISA	261	127	7
Shirdel et al. [64]	2017	Iran	Cross-sectional	ELISA	440	189	8
Tlamcani et al. [65]	2017	Morocco	Cross-sectional	CMIA	3440	1367	7
Aleem et al. [66]	2018	Pakistan	Cross-sectional	LAT	360	170	8
(Eshratkhah Mohammadnejad et al. [67]	2018	Iran	Cross-sectional	ELISA	620	117	7
(Fallahizadeh et al. [68]	2018	Iran	Cross-sectional	ELISA	276	85	7
Rashno et al. [69]	2018	Iran	Cross-sectional	ELISA	98	34	7
Sardarian et al. [70]	2018	Iran	Cross-sectional	ELISA	653	167	6
Abdul-Ghani et al. [71]	2019	Yemen	Cross-sectional	ELISA	379	71	6
(Al-Adhroey et al. [72]	2019	Yemen	Cross-sectional	ELISA	420	89	7
Khademi et al. [73]	2019	Iran	Cross-sectional	ELISA	360	103	8
Rashno et al. [74]	2019	Iran	Cross-sectional	ELISA	98	34	8
Mosawi et al. [75]	2019	Afghanistan	Cross-sectional	ELISA	431	207	7
(Rahmati-Balaghaleh et al. [76]	2019	Iran	Cross-sectional	ELISA	208	114	7
Sadiqui et al. [77]	2019	Pakistan	Cross-sectional	IFFT	500	54	6
Sharifi et al. [78]	2019	Iran	Cross-sectional	ELISA	250	76	7
Abdelbaset et al. [79]	2020	Egypt	Cross-sectional	ELISA	96	29	7
Al-Hakami et al. [80]	2020	Saudi Arabia	Cross-sectional	ELISA	190	52	7
Ali et al. [81]	2020	Pakistan	Cross-sectional	ELISA	222	30	6
Edrees & Ibrahim [82]	2020	Iraq	Cross-sectional	ELISA	150	40	7
(Hoummadi et al. [83]	2020	Morocco	Cross-sectional	ELISA	5578	1607	8
(Jahantigh et al. [84]	2020	Iran	Cross-sectional	ELISA	90	13	8

Mohajab et al. [85]	2020	Saudi Arabia	cross-sectional	ELISA	2754	38	8
Qamer et al. [86]	2020	Saudi Arabia	Cross-sectional	ELISA	306	102	7
Raissi et al. [87]	2020	Iran	Case-control	ELISA	189	75	8
(Al-Shammari & Iqbal [88]	2021	Kuwaiti	Cross-sectional	ELISA	280	41	7
Al-Yami et al. [89]	2021	Saudi Arabia	Cross-sectional	ELISA	500	105	7
(Majda Laboudi et al. [90]	2021	Morocco	Cross-sectional	ELISA	637	299	8
Mahmood & Kahya [91]	2021	Iraq	Case-control	ELISA	109	43	7
Soltani et al. [92]	2021	Iran	Cross-sectional	ELISA	88	30	7
Yusuf et al. [93]	2021	Somalia	Cross-sectional	ELISA	307	159	7
Nabizadeh et al. [94]	2022	Iran	Cross-sectional	CLIA	2726	722	8
Hassan et al. [95]	2023	Somalia	Cross-sectional	ELISA	403	182	7

References

1. Kassem HH, Morsy TA. The prevalence of anti-Toxoplasma antibodies among pregnant women in Benghazi, (S.P.L.A.J.) Libya. J Egypt Soc Parasitol. 1991;21:69–74.
2. El-nawawy A, Soliman AT, Azzouni O El, Amer E, Karim MA, Demian S, et al. Maternal and Neonatal Prevalence of Toxoplasma and Cytomegalovirus (CMV) Antibodies and Hepatitis-B Antigens in an Egyptian Rural Area. J Trop Pediatr. 1996;42 June:154–7.
3. Dar FK, Alkarmi T, Uduman S, Abdulrazzaq Y, Grundsell H, Hughes P. Gestational and neonatal toxoplasmosis: regional seroprevalence in the United Arab Emirates. Eur J Epidemiol. 1997;13:567–71.
4. Al-mulhim AA, Al-qurashi AM. SERO-PREVALENCE OF TOXOPLASMOSIS IN PREGNANT MOTHERS AND NEW BORN INFANTS IN EASTERN PROVINCE , كاملة بمناعة يتمتع الذي , ولكن ، أعراض أية بلازما التلكسو بطفيلي ، J Family Community Med. 2001;8:45–8.
5. Ghazi HO, Telmesani M, Mahomed MF. TORCH Agents in Pregnant. Med Princ Pract. 2002;11:180–2.
6. Noorbakhsh S, Mamishi S, Rimaz S. Toxoplasmosis in Primiparus Pregnant Women and Their Neonates S. Iran J Publ Heal. 2002;31:51–4.
7. Elnahas A, Gerais AS, Elbashir M, Eldien ES, Adam I. Toxoplasmosis in pregnant Sudanese women. Saudi Med J. 2003;24:868-870.

8. Jumaian NF. Seroprevalence and risk factors for Toxoplasma infection in pregnant women in Jordan. *East Mediterr Heal J*. 2005;11:45–51.
9. Al-harhi SA, Jamjoom M, Hani O. Seroprevalence of Toxoplasma gondii among pregnant women in Makkah , Saudi Arabia Seroprevalence of Toxoplasma Gondii Among Pregnant Women in Makkah , Saudi Arabia باستخدام المكرمة مكة مدينة في لـماوحلا النساء عند التوكسوبلازما لـيفطب الإصابة نسبة المصلية رات Umm Al-Qura Univ J Sci Med Eng. 2006;18:217–27.
10. Sharifi-mood B, Hashemi M, Salehi M, Branch S, Naderi M. Seroepidemiology of Toxoplasma Infection in the Pregnant Women in Zahedan , Southeast of Iran. *J Res Health Sci*. 2006;6 January:2–3.
11. Mansouri B El, Rhajaoui M, Sebti F, Amarir F, Laboudi M, Bchitou R, et al. Seroprevalence of toxoplasmosis in pregnant women in Rabat, Morocco. *Bull Soc Pathol Exot*. 2007;100:289–90.
12. Iqbal J, Khalid N. Detection of acute Toxoplasma gondii infection in early pregnancy by IgG avidity and PCR analysis. *J Med Microbiol*. 2007;56:1495–9.
13. Saeedi M, Marjani GRV and A. Seroepidemiologic Evaluation of Anti-toxoplasma Antibodies among Women in North of Iran. *Pakistan J Biol Sci*. 2007;10:2359–62.
14. Abdi J, Shojaee S, Mirzaee A, Keshavarz H. Seroprevalence of Toxoplasmosis in Pregnant Women in Ilam Province, Iran. *Iran J Parasitol*. 2008;3:34–7.
15. Fallah M, Rabiee S, And MM, Taherkhani H. Seroepidemiology of toxoplasmosis in primigravida women in Hamadan , Islamic Republic of Iran , 2004. *East Mediterr Heal J*. 2008;14:163–71.
16. Ibrahim HM, Mohamed AH, El-Sharaawy AA, El-Shqanqery HE. Molecular and serological prevalence of Toxoplasma gondii in pregnant women and sheep in Egypt. *Asian Pac J Trop Med*. 2017;10:996–1001.
17. Nijem K, Al-Amleh S. Seroprevalence and associated risk factors of toxoplasmosis in pregnant women in Hebron district , Palestine. *La Rev Santé la Méditerranée Orient*. 2009;15:1278–84.
18. Jameel GH, Al-azzawi AMK, Salman FK. Antigen reaction in detection of toxoplasma gondii antibodies in the serum of pregnant women household pets in Baquba sector. *Biochem Cell Arch*. 2020;20:3509–11.
19. Mohammad HIA, Amin TT, Balaha MH, Moghannum MSA. Toxoplasmosis among the pregnant women attending a Saudi maternity hospital: seroprevalence and possible risk factors. *Ann Trop Med Parasitol*. 2010;104:493–504.
20. Sellami H, Amri H, Cheikhrouhou F, Sellami A, Makni F, Trabelsi H, et al. État actuel de la toxoplasmose dans la région de Sfax, Tunisie Toxoplasmosis in Sfax, Tunisia. *Bull Soc Pathol Exot*. 2010;103:37–40.
21. Almogren A. Antenatal screening for Toxoplasma gondii infection at a tertiary care hospital in Riyadh, Saudi Arabia. *Ann Saudi Med*. 2011;31 December:569–72.
22. Mohammed TK. SEROPREVALENCE OF TOXOPLASMA GONDII AMONG PREGNANT WOMEN IN BAGHDAD CITY. *Inst Med Technol*. 2011;23:12–21.
23. Amany MAE-G, and Merwad AMA. Epidemiology and Molecular Detection of Zoonotic Toxoplasma gondii in Cat Feces and Seroprevalence of Anti-Toxoplasma gondii Antibodies in Pregnant Women and Sheep. *Life Sci J*. 2012;9:133–46.

24. Saad M. Bin Dajem, Almushait MA. Detection of *Toxoplasma gondii* DNA by PCR in blood samples collected from pregnant Saudi women from the Aseer region, Saudi Arabia. *Ann Saudi Med.* 2012;32:507–12.
25. El Deeb HK, Salah-Eldin H, Khodeer S, Allah AA. Prevalence of *Toxoplasma gondii* infection in antenatal population in Menoufia governorate, Egypt. *Acta Trop.* 2012;124:185–91.
26. Maha H. Elamin. Molecular detection and prevalence of *Toxoplasma gondii* in pregnant women in Sudan. *African J Microbiol Res.* 2012;6:308–11.
27. Hajsoleimani F, Ataeian A, Mazloomzadeh S. Seroprevalence of *Toxoplasma gondii* in Pregnant Women and Bioassay of IgM. *Iran J Parasitol.* 2012;7:82–6.
28. Babaie J, Amiri S, Mostafavi E, Hassan N, Lotfi P, Rastaghi ARE, et al. Seroprevalence and risk factors for *toxoplasma gondii* infection among pregnant women in northeast Iran. *Clin Vaccine Immunol.* 2013;20:1771–3.
29. Ben Abdallah R, Siala E, Bouafsoun A, Maatoug R, Souissi O, Aoun K, et al. Dépistage de la toxoplasmose materno-foetale: étude des cas suivis à l'Institut Pasteur de Tunis (2007-2010). *Bull la Soc Pathol Exot.* 2013;106:108–12.
30. Fakhfakh N, Kallel K, Ennigro S, Kaouech E, Belhadj S, Chaker E. Facteurs de risque pour *toxoplasma gondii* et statut immunitaire des femmes parturientes: Relation de cause à effet? *Tunisie Medicale.* 2013;91:188–90.
31. Panah Abolghasem Siyadat M assadi, Katayoun Bahman Soufiani GB, Gharachorlou A, Zeydi AE. Seroprevalence of *Toxoplasma gondii* infection among pregnant women in Amol, Northern Iran. *Life Sci J.* 2013;10:18–21.
32. Abdel-Raouff M, Elbasheir MM. Sero-prevalence of *Toxoplasma gondii* infection among pregnant women attending antenatal clinics in Khartoum and Omdurman Maternity Hospitals, Sudan. *J Coast Life Med.* 2014;2:496–9.
33. Ahmed HA, Shafik SM, Alli MEM, Elghamry ST, Ahmed AA. Molecular detection of *Toxoplasma gondii* DNA in milk and risk factors analysis of seroprevalence in pregnant women at Sharkia, Egypt. *Vet World.* 2014;7:594–600.
34. Almushait MA, Dajem SMB, Elsherbiny NM, Eskandar MA, Al Azraqi TA, Makhoul LM. Seroprevalence and risk factors of *Toxoplasma gondii* infection among pregnant women in south western, Saudi Arabia. *J Parasit Dis.* 2014;38:4–10.
35. Aqeely H, El-Gayar EK, Perveen Khan D, Najmi A, Alvi A, Bani I, et al. Seroepidemiology of *toxoplasma gondii* amongst pregnant women in Jazan Province, Saudi Arabia. *J Trop Med.* 2014;2014.
36. Ashankyty IM. Seroprevalence of *Toxoplasma gondii* among pregnant women visiting maternity hospital in Hail, KSA. *Life Sci J.* 2014;11:355–9.
37. Hadi G, Ghomashlooyan M, Hooshyar H. Seroprevalence of *Toxoplasma gondii* Infection among Pregnant Women Admitted at Shahid Akbar Abadi Hospital, Tehran, Iran, 2010-2013. *J Med Microbiol Infec Dis,.* 2014;2:16–8.
38. Laboudi M, El Mansouri B, Rhajaoui M. The role of the parity and the age in acquisition of toxoplasmosis among pregnant women in Rabat - Morocco. *Int J Innov Appl Stud.* 2014;6:488–92.

39. Sharbatkhori M, Moghaddam YD, Pagheh AS, Mohammadi R, Mofidi HH, Shojaee S. Seroprevalence of *Toxoplasma gondii* infections in pregnant women in Gorgan City, Golestan Province, Northern Iran-2012. *Iran J Parasitol.* 2014;9:181–7.
40. Yad MJ, Jomehzadeh N, Sameri MJ, Noorshahi N. Seroprevalence of anti-toxoplasma *gondii* antibodies among pregnant woman in south Khuzestan, Iran. *Jundishapur J Microbiol.* 2014;7:5–8.
41. Elsafi SH, Al-Mutairi WF, Al-Jubran KM, Abu Hassan MM, Al Zahrani EM. Toxoplasmosis seroprevalence in relation to knowledge and practice among pregnant women in Dhahran, Saudi Arabia. *Pathog Glob Health.* 2015;109:377–82.
42. Kamal AM, Ahmed AK, Abdellatif MZM, Tawfik M, Hassan EE. Seropositivity of toxoplasmosis in pregnant women by ELISA at Minia university hospital, Egypt. *Korean J Parasitol.* 2015;53:605–10.
43. Ahmadpour M, Daryani A, Ebrahimnejad Z, Gholami S, Ahmadpour E, Borhani S, et al. Seroprevalence of anti-Toxoplasma IgG and IgM among individuals who were referred to medical laboratories in Mazandaran province, northern Iran. *J Infect Public Health.* 2016;9:75–80.
44. Akhlaghi L, Tabatabaie F, Hadighi R, Maleki F, Hajialiani F, Dayer MS, et al. Diagnosis of acute toxoplasmosis in pregnant women referred to therapeutic centers of Alborz Province (Iran) using immunoglobulin G avidity ELISA technique. *Asian Pacific J Trop Dis.* 2016;6:864–7.
45. Al-Eryani SMA, Al-Mekhlafi AM, Al-Shibani LA, Mahdy MMK, Azazy AA. *Toxoplasma gondii* infection among pregnant women in Yemen: Factors associated with high seroprevalence. *J Infect Dev Ctries.* 2016;10:667–72.
46. Alghamdi J, Elamin MH, Alhabib S. Prevalence and genotyping of *Toxoplasma gondii* among Saudi pregnant women in Saudi Arabia. *Saudi Pharm J.* 2016;24:645–51.
47. Bassiony H, Soliman N, Tawab S, Eissa S, Eissa A. Sero-prevalence and risk factors associated with toxoplasma *gondii* infection among pregnant women in Alexandria, Egypt. *Int J Reprod Contraception, Obstet Gynecol.* 2016;5:4220–7.
48. Imam NFA, Azzam EAA, Attia AA. Seroprevalence of *Toxoplasma gondii* among pregnant women in Almadinah Almunawwarah KSA. *J Taibah Univ Med Sci.* 2016;11:255–9.
49. Majid A, Khan S, Jan AH, Taib M, Adnan M, Ali I, et al. Chronic toxoplasmosis and possible risk factors associated with pregnant women in Khyber Pakhtunkhwa. *Biotechnol Biotechnol Equip.* 2016;30:733–6.
50. Mohaghegh MA, Kalani H, Hashemi M, Hashemi S, Yazdnezhad SK, Hejazi SH, et al. Toxoplasmosis-related risk factors in pregnant women in the North Khorasan province, Iran. *Int J Med Res Heal Sci.* 2016;5:370–4.
51. Mohamed K, Bahathiq A, Degnah N, Basuni S, Mahdi AB, Malki A Al, et al. Detection of *Toxoplasma gondii* infection and associated risk factors among pregnant women in Makkah Al Mukarramah, Saudi Arabia. *Asian Pacific J Trop Dis.* 2016;6:113–9.
52. Rostamzadeh Khameneh Z, Hanifian H, Rostamzadeh A. Seroprevalence of Toxoplasmosis in Pregnant Women in Urmia, Iran. *Int J Enteric Pathog.* 2016;In Press In Press:4–6.
53. Ahmadpour GR, Ezatpour B, Hadighi R, Oormazdi H, Akhlaghi L, Tabatabaei F, et al. Seroepidemiology of *Toxoplasma gondii* infection in pregnant women in west Iran: determined by ELISA and PCR analysis. *J Parasit Dis.* 2017;41:237–42.

54. Alanazi FB, Hassan TM, Alanazi WF. Seroprevalence of *Toxoplasma gondii* among pregnant Saudi woman in Arar, Northern Borders Province, Saudi Arabia. *Kasr Al Ainy Med J*. 2017;23:104.
55. Garedaghi Y, Firozivand Y. Assessment of pregnant women toxoplasmosis by ELISA method in Miandoab city, Iran. *Int J Women's Heal Reprod Sci*. 2017;5:72–5.
56. Ibrahim HM, Huang P, Salem TA, Talaat RM, Nasr MI, Xuan X, et al. Prevalence of *Neospora caninum* and *Toxoplasma gondii* Antibodies in Pregnant women from Northern Iran. *Am J Trop Med Hyg*. 2009;80:263–7.
57. Laboudi M, Sadak A. Serodiagnosis of Toxoplasmosis: The effect of measurement of IgG avidity in pregnant women in Rabat in Morocco. *Acta Trop*. 2017;172:139–42.
58. Mahdy MAK, Alareqi LM, Abdul-Ghani R, Al-Eryani SMA, Al-Mikhlafe AA, Al-Mekhlafi AM, et al. A community-based survey of *Toxoplasma gondii* infection among pregnant women in rural areas of Taiz governorate, Yemen: The risk of waterborne transmission. *Infect Dis Poverty*. 2017;6:4–9.
59. Naghili B, Abbasalizadeh S, Tabrizi S, Rajaii M, Akramiyan M, Alikhah H, et al. Comparison of IIF, ELISA and IgG avidity tests for the detection of anti-toxoplasma antibodies in single serum sample from pregnant women. *Infez Med*. 2017;25:50–6.
60. Nahouli H, El Arnaout N, Chalhoub E, Anastadiadis E, El Hajj H. Seroprevalence of Anti-*Toxoplasma gondii* Antibodies Among Lebanese Pregnant Women. <https://home.liebertpub.com/vbz>. 2017;17:785–90.
61. Nazir MA. Prevalence of periodontal disease, its association with systemic diseases and prevention. *Int J Health Sci (Qassim)*. 2017;11:72.
62. Norouzi LY, Sarkari B, Asgari Q, Khabisi SA. Molecular Evaluation and Seroprevalence of Toxoplasmosis in Pregnant Women in Fars province, Southern Iran | *Annals of Medical and Health Sciences Research*. *Ann Med Health Sci Res*. 2017;7:16–9.
63. Shieh M, Didehdar M, Hajihosseini R, Ahmadi F, Eslamirad Z. Toxoplasmosis: Seroprevalence in pregnant women, and serological and molecular screening in neonatal umbilical cord blood. *Acta Trop*. 2017;174:38–44.
64. Shirdel S, Sharbatkhori M, Pagheh AS, Dadimoghadam Y, Soosaraie M, Gholami S. Seroepidemiology of *Toxoplasma gondii* infection in pregnant women and risk factors of the disease in Golestan Province, Iran. *J Maz Univ Med Sci*. 2017;27:63–71.
65. Tlamcani Z, Yahyaoui G, Mahmoud M. Prevalence of immunity to toxoplasmosis among pregnant women in University Hospital center Hassan II of FEZ city (Morocco). *Acta Medica Int*. 2017;4:43.
66. Aleem U, Ullah S, Qasim M, Suliman M. Seroprevalence of Toxoplasmosis in Pregnant Women in Matta , Upper Swat , Khyber Pakhtunkhwa , Pakistan. *J Saidu Med Coll*. 2018;:103–6.
67. Eshratkhah Mohammadnejad A, Eslami G, Shamsi F, Pirnejad A, Samie A, Safabakhsh J, et al. Prevalence of food-borne *Toxoplasma* in pregnant women population of Urmia, Iran. *J Food Qual Hazards Control*. 2018;5:17–23.
68. Fallahizadeh S, Jelowdar A, Kazemi F, Cheraghian B. Seroprevalence of Anti-*Toxoplasma* IgG and IgM among Pregnant Women of Shush County, Southwest of Iran. *Int J Infect*. 2018;5:1–4.
69. Rashno MM, Fallahi S, Arab-Mazar Z, Dana H. Seromolecular assess of *Toxoplasma gondii* infection in

pregnant women and neonatal umbilical cord blood. EXCLI J. 2019;18:1.

70. Sardarian K, Maghsood A, Farimani M, Hajiloi M, Saidijam M, Rezaeepoor M, et al. Evaluation of *Toxoplasma gondii* B1 gene in Placental Tissues of Pregnant Women with Acute Toxoplasmosis. Adv Biomed Res. 2018;7:119.

71. Abdul-Ghani R, Al-Nahari A, Yousef A, Al-Haj A-A, Aqlan A, Jaadan E, et al. *Toxoplasma gondii* Infection in Relation to Pregnancy Characteristics and Bad Obstetric History among Pregnant Women Seeking Healthcare in Sana'a City, Yemen. Yemeni J Med Sci. 2019;13:10–22.

72. Al-Adhroey AH, Mehrass AAKO, Al-Shammakh AA, Ali AD, Akabat MYM, Al-Mekhlafi HM. Prevalence and predictors of *Toxoplasma gondii* infection in pregnant women from Dhamar, Yemen. BMC Infect Dis. 2019;19:1–9.

73. Khademi SZ, Ghaffarifar F, Dalimi A, Davoodian P, Abdoli A. Prevalence and risk factors of *Toxoplasma gondii* infection among pregnant women in Hormozgan province, south of Iran. Iran J Parasitol. 2019;14:167–73.

74. Rashno MM, Fallahi S, Arab-Mazar Z, Dana H. Seromolecular assess of *Toxoplasma gondii* infection in pregnant women and neonatal umbilical cord blood. EXCLI J. 2019;18:1–7.

75. Mosawi SH, Zarghona Z, Dalimi A. Particularly neglected in countries with other challenges : High *Toxoplasma gondii* seroprevalence in pregnant women in Kabul , Afghanistan , while a low proportion know about the parasite. PLoS One. 2019;14:1–9.

76. Rahmati-Balaghaleh M, Hosseini Farash BR, Zarean M, Hatami-Pourdehno S, Mirahmadi H, Jarahi L, et al. Diagnosis of acute toxoplasmosis by IgG avidity method in pregnant women referred to health centers in south-eastern Iran. J Parasit Dis. 2019;43:517–21.

77. Sadiqui S, Shah SRH, Almagadam BS, Shakeela Q, Ahmad S. Distribution of *Toxoplasma gondii* IgM and IgG antibody seropositivity among age groups and gestational periods in pregnant women. F1000Research. 2019;7:1–12.

78. Sharifi K, Hosseini Farash BR, Tara F, Khaledi A, Sharifi K, Shamsian SAA. Diagnosis of acute toxoplasmosis by igg and igm antibodies and igg avidity in pregnant women from Mashhad, eastern Iran. Iran J Parasitol. 2019;14:639–45.

79. Abdelbaset AE, Hamed MI, Abushahba MFN, Rawy MS, Sayed ASM. *Toxoplasma gondii* seropositivity and the associated risk factors in sheep and pregnant women in El-Minya Governorate , Egypt. Vet World. 2020;13:13–5.

80. Al-Hakami AM, Paul E, Al-Abed F, Alzoani AA, Shati AA, Assiri MI, et al. Prevalence of toxoplasmosis, rubella, cytomegalovirus, and herpes (TORCH) infections among women attending the antenatal care clinic, maternity hospital in Abha, Southwestern Saudi Arabia. Saudi Med J. 2020;41:757–62.

81. Ali S, Amjad Z, Khan TM, Maalik A, Iftikhar A, Khan I, et al. Occurrence of *Toxoplasma gondii* antibodies and associated risk factors in women in selected districts of Punjab province , Pakistan. Parasitology. 2020;147:1133–1139.

82. Edrees T, Ibrahim RH. Seroprevalence of *Toxoplasma Gondii* among pregnant women visiting antenatal Clinic at the Mosul City , Iraq . P J M H S. 2020;14:1046–9.

83. Hoummadi L, Berrouch S, Amraouza Y, Adel A, Mriouch M, Soraa N, et al. Seroprevalence of

toxoplasmosis in pregnant women of the marrakech-safi region, morocco. *Afr Health Sci.* 2020;20:59–63.

84. Jahantigh FF, Rasekh M, Ganjali M, Sarani A. Seroprevalence of *Toxoplasma Gondii* infection among pregnant women and small ruminant populations in Sistan Region, Iran. *Iran J Vet Med.* 2020;14:239–50.

85. Mohajab AH, Alshehri HZ, Shati RO, Alshehri AA, Alafghani MA, Alasmari A, et al. Anti-toxoplasma Antibody Prevalence and Cost-effectiveness in Pregnant Women at the King Abdulaziz University Hospital, Jeddah, Saudi Arabia. *Cureus.* 2020;12:1–8.

86. Qamer S, S.S.R. R, Raoof S, Kamal SM, Khan S. Sero-prevalence of toxoplasmosis among pregnant women attending an ante-natal clinic at a teaching hospital in al Kharj, Saudi Arabia. *Trop Biomed.* 2020;37:186–93.

87. Raissi V, Taghipour A, Navi Z, Etemadi S, Sohrabi Z, Sohrabi N, et al. Seroprevalence of *Toxoplasma gondii* and *Toxocara* spp. infections among pregnant women with and without previous abortions in the west of Iran. *J Obstet Gynaecol Res.* 2020;46:382–8.

88. Al-Shammari N, Iqbal J. Decreasing trend in toxoplasma seroprevalence among pregnant women in Kuwait. *East Mediterr Heal J.* 2021;27:67–75.

89. Al-Yami FS, Dar FK, Yousef AI, Al-Qurouni BH, Al-Jamea LH, Rabaan AA, et al. A pilot study on screening for gestational/congenital toxoplasmosis of pregnant women at delivery in the Eastern Province of Saudi Arabia. *Saudi Pharm J.* 2021;29:343–50.

90. Laboudi M, Taghy Z, Duieb O, Peyron F, Sadak A. *Toxoplasma gondii* seroprevalence among pregnant women in Rabat, Morocco. *Trop Med Health.* 2021;49.

91. Mahmood MT, Kahya HFH. Serological study of torch complex in pregnant women with an obstetric history in mosul city, iraq. *Curr Trends Immunol.* 2021;22:95–102.

92. Soltani S, Ghaffari AD, Kahvaz MS, Sabaghan M, Pashmforosh M, Foroutan M. Detection of Anti-*Toxoplasma gondii* IgG and IgM Antibodies and Associated Risk Factors during Pregnancy in Southwest Iran. *Infect Dis Obstet Gynecol.* 2021;2021.

93. Yusuf AA, Hassan-Kadle AA, Ibrahim AM, Hassan-Kadle MA, Yasin AM, Khojaly M, et al. Prevalence of Anti-*Toxoplasma gondii* and Anti-*Brucella* Spp. Antibodies in Pregnant Women From Mogadishu, Somalia. *Front Reprod Heal.* 2021;3 August:1–5.

94. Nabizadeh E, Ghotaslou A, Salahi B, Ghotaslou R. The Screening of Rubella Virus, Cytomegalovirus, Hepatitis B Virus, and *Toxoplasma gondii* Antibodies in Prepregnancy and Reproductive-Age Women in Tabriz, Iran. *Infect Dis Obstet Gynecol.* 2022;2022:2–6.

95. Hassan SA, Tamomh AG, Hassan DA, Ahmed NR. Seroprevalence of anti-*Toxoplasma gondii* antibodies and associated risk factors in pregnant women in Somalia. *Acta Trop.* 2023;238 September 2022:106774.